Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1 -m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Blood (2024) 144 (Supplement 1): 2880.

https://doi.org/10.1182/blood-2024-199170

Published: 2024

Journal Articles

Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database

Ted M. Getz, Tariq Kewan, Jan Philipp Bewersdorf, Jessica M. Stempel, Luca Lanino, Wei Wei, Najla H. Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L. Uy, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine M. McMahon, Rory M. Shallis, Joshua F Zeidner, Michael R. Savona, Somedeb Ball, Namrata S. Chandhok, Constantine Logothetis, Aram Bidikian, Gail J. Roboz, Benjamin Rolles, Eunice S. Wang, Amyah C. Harris, Maria L Amaya, Hayley Hawkins, Justin Grenet, Zhuoer Xie, Yazan F. Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop K Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vasiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Maximilian Stahl, Matteo Giovanni Della Porta, Rami S. Komrokji, Amer M. Zeidan

Blood (2024) 144 (Supplement 1): 3219.

https://doi.org/10.1182/blood-2024-202075

Published: 2024

Journal Articles

STAT3-VDAC1 Axis Modulates Mitochondrial Function and Plays a Critical Role in the Survival of Leukemic Stem Cells

Kellen B Gil, Jamie Borg, Rosana Moreira Pereira, Anagha Inguva Sheth, Jeremy Rahkola, William Showers, Angelo D'Alessandro, Christine M. McMahon, Daniel A Pollyea, Austin E Gillen, Maria L Amaya

Blood (2024) 144 (Supplement 1): 2722.

https://doi.org/10.1182/blood-2024-207887

Published: 2024

Journal Articles

Access to Novel Therapies Impacts Overall Survival (OS) in Low Socioeconomic (SES) Acute Myeloid Leukemia (AML) Patients (Pts)

Cassandra Duarte, Diana Abbott, Christine M. McMahon, Andrew Kent, Marc Schwartz, Jonathan Gutman, Daniel A Pollyea, Maria L Amaya

Blood (2024) 144 (Supplement 1): 3803.

https://doi.org/10.1182/blood-2024-201061

Published: 2024

Journal Articles

Efficacy and Molecular Predictors of Response and Survival for Venetoclax/Azacitidine Therapy in Relapsed or Refractory Acute Myeloid Leukemia

Jason S. Gilbert, Megan Connor, Grace Bosma, Christine M. McMahon, Maria L Amaya, Jonathan Gutman, Marc Schwartz, Andrew Kent, Diana Abbott, Daniel A Pollyea

Blood (2024) 144 (Supplement 1): 4266.

https://doi.org/10.1182/blood-2024-199862

Published: 2024

Journal Articles

Results from a Clinical Study of the All-Oral Regimen of CC-486 (Oral Azacitidine) and Venetoclax for Newly Diagnosed and Relapsed and Refractory Acute Myeloid Leukemia

Maria L Amaya, Christine M. McMahon, Marc Schwartz, Jonathan Gutman, Andrew Kent, Diana Abbott, Connor Sohalski, Jessica Dell-Martin, Ayele Belachew, Brett M Stevens, Craig T Jordan, Daniel A Pollyea

Blood (2024) 144 (Supplement 1): 4259.

https://doi.org/10.1182/blood-2024-202839

Published: 2024

Journal Articles

Comparison of Myeloablative Conditioning with a Total Body Irradiation-Based Regimen Versus a Chemotherapy-Based Regimen in Adult Patients Undergoing Umbilical Cord Blood Stem Cell Transplant for Ph-Negative Acute Lymphoblastic Leukemia

Jason S. Gilbert, Andrew Kent, Jonathan Gutman, Maria L Amaya, Christine M. McMahon, Daniel A Pollyea, Marc Schwartz

Blood (2024) 144 (Supplement 1): 7280.

https://doi.org/10.1182/blood-2024-200993

Published: 2024

Journal Articles

Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy

Blood (2024) 144 (Supplement 1): 969.

https://doi.org/10.1182/blood-2024-199267

Published: 2024

Journal Articles

Treatment-Related and De Novo Ccus Have Similar Molecular Features and Risk of Progression to Myeloid Malignancies

Jennifer Santos, Diana Abbott, Grace Bosma, Andrew Kent, Marc Schwartz, Christine M. McMahon, Jonathan Gutman, Daniel A Pollyea, Maria L Amaya

Blood (2024) 144 (Supplement 1): 5649.

https://doi.org/10.1182/blood-2024-201062

Published: 2024

Journal Articles

Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts

Blood (2024) 144 (Supplement 1): 1828.

https://doi.org/10.1182/blood-2024-199336

Published: 2024

Journal Articles

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica M. Stempel, Luca Lanino, Najla H. Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L. Uy, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine M. McMahon, Rory M. Shallis, Joshua F Zeidner, Michael R. Savona, Stacey M. Frumm, Shougat Barua, Namrata S. Chandhok, Constantine Logothetis, Aram Bidikian, Ted M. Getz, Gail J. Roboz, Eunice S. Wang, Amyah C. Harris, Maria L Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan F Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop K Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Giovanni Della Porta, Rami S. Komrokji, Amer M. Zeidan, Maximilian Stahl

Blood (2024) 144 (Supplement 1): 664.

https://doi.org/10.1182/blood-2024-208034

Published: 2024

Journal Articles

Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1- m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Blood (2024) 144 (Supplement 1): 214.

https://doi.org/10.1182/blood-2024-198218

Published: 2024

Journal Articles

Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia

Blood (2024) 144 (Supplement 1): 211.

https://doi.org/10.1182/blood-2024-194384

Published: 2024

Journal Articles

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

Blood (2023) 142 (Supplement 2): LBA-5.

https://doi.org/10.1182/blood-2023-192042

Published: 2023

Journal Articles

Socioeconomic Status Is a Mediator of Overall Survival in Acute Myeloid Leukemia (AML)

Cassandra Duarte, Diana Abbott, Grace N Bosma, Christine M. McMahon, Jonathan A Gutman, Marc Schwartz, Daniel Pollyea, Maria L Amaya

Blood (2023) 142 (Supplement 1): 5176.

https://doi.org/10.1182/blood-2023-174996

Published: 2023

Journal Articles

Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) - a Large, Multicenter, Retrospective Analysis

Blood (2023) 142 (Supplement 1): 4613.

https://doi.org/10.1182/blood-2023-178728

Published: 2023

Journal Articles

The Genomic and Transcriptomic Landscape of Myeloid Sarcoma and Associated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 292.

https://doi.org/10.1182/blood-2023-182967

Published: 2023

Journal Articles

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study

Blood (2023) 142 (Supplement 1): 2907.

https://doi.org/10.1182/blood-2023-189762

Published: 2023

Journal Articles

Results from a Phase (Ph) 1 Clinical Study of the All-Oral Regimen of CC-486 and Venetoclax for Relapsed and Refractory Acute Myeloid Leukemia

Maria L Amaya, Christine M. McMahon, Marc Schwartz, Jonathan A Gutman, Connor Sohalski, Jennifer Tobin, Austin E Gillen, Anagha Inguva Sheth, Brett M Stevens, Clayton Smith, Craig T. Jordan, Daniel A. Pollyea

Blood (2023) 142 (Supplement 1): 2914.

https://doi.org/10.1182/blood-2023-182966

Published: 2023

Journal Articles

Age-Adapted Chemotherapy for Adults >40 Years Old with Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia: Single Center Outcomes

Marc Schwartz, Jonathan A Gutman, Christine M. McMahon, Maria L Amaya, Daniel A. Pollyea, Matthew Witkowski, Mohd Minhajuddin, Clayton Smith, Craig T. Jordan

Blood (2023) 142 (Supplement 1): 5898.

https://doi.org/10.1182/blood-2023-188298

Published: 2023

NARROW

Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1 -m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database

STAT3-VDAC1 Axis Modulates Mitochondrial Function and Plays a Critical Role in the Survival of Leukemic Stem Cells

Access to Novel Therapies Impacts Overall Survival (OS) in Low Socioeconomic (SES) Acute Myeloid Leukemia (AML) Patients (Pts)

Efficacy and Molecular Predictors of Response and Survival for Venetoclax/Azacitidine Therapy in Relapsed or Refractory Acute Myeloid Leukemia

Results from a Clinical Study of the All-Oral Regimen of CC-486 (Oral Azacitidine) and Venetoclax for Newly Diagnosed and Relapsed and Refractory Acute Myeloid Leukemia

Comparison of Myeloablative Conditioning with a Total Body Irradiation-Based Regimen Versus a Chemotherapy-Based Regimen in Adult Patients Undergoing Umbilical Cord Blood Stem Cell Transplant for Ph-Negative Acute Lymphoblastic Leukemia

Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy

Treatment-Related and De Novo Ccus Have Similar Molecular Features and Risk of Progression to Myeloid Malignancies

Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1- m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

Socioeconomic Status Is a Mediator of Overall Survival in Acute Myeloid Leukemia (AML)

Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) - a Large, Multicenter, Retrospective Analysis

The Genomic and Transcriptomic Landscape of Myeloid Sarcoma and Associated Acute Myeloid Leukemia

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study

Results from a Phase (Ph) 1 Clinical Study of the All-Oral Regimen of CC-486 and Venetoclax for Relapsed and Refractory Acute Myeloid Leukemia

Age-Adapted Chemotherapy for Adults >40 Years Old with Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia: Single Center Outcomes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only